You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: Colorado Research Partners LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Evidence-Based Pain Intervention for Veterans: Leveraging Mobile and Social Media

    SBC: Pro-Change Behavior Systems Inc            Topic: NCCIH

    Chronic musculoskeletal pain creates a significant public health burden, and Veterans are disproportionately affected. The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), all three conditions (Post-deployment Multi-symptom Disorder (PMD), and other multi-symptom syndromes can complicate and reduce the effectiveness of pain treatment. Furthermore, the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II

    SBC: MBC Pharma, Inc.            Topic: NCI

    Project Summary AbstractThe overall aim of this project is to further develop a novel gemcitabine ibandronate conjugate alone and or as part of a combination therapy for the treatment of osteosarcoma and associated metastasesThe conjugate consists of chemically linked anticancer antimetabolite Gemcitabine and the bone homing bisphosphonate IbandronateThe novel conjugate directly addresses the limi ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Topical proprietary biologic to treat oral mucositis

    SBC: Allander Biotechnologies            Topic: NIDCR

    Summary Oral mucositisa severe oral ulcerationis a common toxic effect of radioor chemoradio therapy and a limiting factor to using the maximum dose of radiation for effective cancer treatmentAt leastand up toof cancer patients treated with standard chemotherapy regimens or upper body radiation develop oral mucositisIntensity modulated RTIMRTlessens chronic side effectsbut not the acute toxicity s ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Electrochemical Paper-Based Analytical Devices for Metal Determination

    SBC: Access Sensor Technologies LLC            Topic: NIEHS

    Project Summary The goal of this project is to develop a new sampling and analysis system combining two new technologiesA lightweight ultrasonic sampler will be paired with an electrochemical paper based analytical deviceePADfor measurement of metals in airborne particulate matterPMExposure to particulate matterPMair pollution ranks as theth leading risk factor for human morbidity and mortality wo ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Micropatterned surfaces for minimizing pediatric gastrostomy tube complications

    SBC: Sharklet Technologies Inc.            Topic: NICHD

    Summary In a variety of diseases and conditions when oral feeding is impossibleenteral feeding through percutaneous gastrostomyPGis necessary to provide long term nutrition for adult and pediatric patientsIt is estimated that overthousand feeding tubes are placed in pediatric patients in the US annuallyHoweverthese patients frequently experience complications associated with PG tube placementLate ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, LLC            Topic: 105

    Neonatal hypoxia ischemiaHIremains a major cause of acute perinatal brain injuryleading ultimately to neurologic dysfunction manifesting as cerebral palsymental retardationand epilepsyUnfortunatelycurrent treatment and prevention strategies in newborns are limitedThere are no currently available therapies to prevent treat and or attenuate brain damage in premature infants other than supportive car ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Micro Patterned Intraocular Lens Membrane for Reducing Incidence of PCO

    SBC: CLEARSIGHT, LLC            Topic: N

    AbstractThe exponential increase of diabetics and the elderly in the U Shas more than tripled the number of cataract surgeries performed in just two decadesAs many as half of these surgeries will lead to posterior capsular opacificationPCOwhich requires follow up Nd YAG laser capsulotomy surgeryWithout this additional procedurepatients can suffer permanent vision loss and disabilityIn many countri ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure, often resulting i death. Granulocyte colony-stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government